BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21239819)

  • 1. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.
    Loh ML
    Hematology Am Soc Hematol Educ Program; 2010; 2010():357-62. PubMed ID: 21239819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.
    Loh ML
    Br J Haematol; 2011 Mar; 152(6):677-87. PubMed ID: 21623760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
    Chang TY; Dvorak CC; Loh ML
    Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of juvenile myelomonocytic leukemia.
    Sakashita K; Matsuda K; Koike K
    Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
    Sakashita K
    Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
    Koike K; Matsuda K
    Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
    De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy.
    Loh ML; Mullighan CG
    Clin Cancer Res; 2012 May; 18(10):2754-67. PubMed ID: 22589484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
    Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
    Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
    Lasho T; Patnaik MM
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Juvenile myelomonocytic leukemia and pediatric myelodysplastic syndromes].
    Strullu M; Leblanc T; Lainey E
    Bull Cancer; 2023 Nov; 110(11):1183-1195. PubMed ID: 37453833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JMML genomics and decisions.
    Niemeyer CM
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature.
    Wintering A; Smith S; Fuh B; Rangaswami A; Dahl G; Chien M; Gruber TA; Dang J; Li LS; Lenzen A; Savelli S; Dvorak CC; Agrawal AK; Stieglitz E
    Pediatr Blood Cancer; 2022 May; 69(5):e29499. PubMed ID: 34939322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
    Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
    Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
    Niemeyer CM; Kratz CP
    Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
    Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
    Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.